Recent advances in targeted strategies for triple-negative breast cancer
Tongji Hospital · Huazhong University of Science and Technology · +3 more institutions
Abstract
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple targeted therapeutic strategies have emerged according to the specific molecules and signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates. Moreover, immune…
Citation impact
- FWCI
- 70.90
- Percentile
- 100%
- References
- 307
Authors
7- SZShuangli ZhuCorresponding
Tongji Hospital, Huazhong University of Science and Technology
- YWYuze Wu
Tongji Hospital, Huazhong University of Science and Technology
- BSBin Song
Shanxi Medical University, Shanxi Academy of Medical Sciences
- MYMing Yi
Zhejiang University
- YYYuheng Yan
Tongji Hospital, Huazhong University of Science and Technology
Topics & keywords
- Triple-negative breast cancer
- Medicine
- Breast cancer
- Pembrolizumab
- Oncology
- Targeted therapy
- Atezolizumab
- Cancer research
- Good health and well-being